AKEBIA THERAPEUTICS, INC. Revenue
AKEBIA THERAPEUTICS, INC. (AKBA) reported Revenue of $49.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $49.13M, a 21.36% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $53.54M, a 6.61% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $57.62M, a 23.93% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $58.77M, a 57.01% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $236.20M, a 47.46% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $160.18M, a 17.70% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $194.62M, a 33.46% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $292.48M, a 38.19% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $49.13M 10-Q · filed 2026-08-05 | $102.67M 10-Q · filed 2026-08-05 | $160.29M derived: sum of 3 quarters · filed 2026-08-05 | $219.06M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $53.54M 10-Q · filed 2026-05-07 | $111.17M derived: sum of 2 quarters · filed 2026-05-07 | $169.93M derived: sum of 3 quarters · filed 2026-05-07 | $232.40M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $57.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $116.39M derived: sum of 2 quarters · filed 2026-02-26 | $178.86M derived: sum of 3 quarters · filed 2026-08-05 | $236.20M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $58.77M 10-Q · filed 2025-11-10 | $121.24M derived: sum of 2 quarters · filed 2026-08-05 | $178.57M 10-Q · filed 2025-11-10 | $225.07M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $62.47M 10-Q · filed 2026-08-05 | $119.81M 10-Q · filed 2026-08-05 | $166.31M derived: sum of 3 quarters · filed 2026-08-05 | $203.73M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $57.34M 10-Q · filed 2026-05-07 | $103.83M derived: sum of 2 quarters · filed 2026-05-07 | $141.26M derived: sum of 3 quarters · filed 2026-05-07 | $184.91M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $46.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $83.92M derived: sum of 2 quarters · filed 2026-02-26 | $127.57M derived: sum of 3 quarters · filed 2026-02-26 | $160.18M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $37.43M 10-Q · filed 2025-11-10 | $81.08M derived: sum of 2 quarters · filed 2025-11-10 | $113.68M 10-Q · filed 2025-11-10 | $169.88M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $43.65M 10-Q · filed 2025-08-07 | $76.25M 10-Q · filed 2025-08-07 | $132.45M derived: sum of 3 quarters · filed 2026-02-26 | $174.50M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $32.61M 10-Q · filed 2025-05-08 | $88.80M derived: sum of 2 quarters · filed 2026-02-26 | $130.85M derived: sum of 3 quarters · filed 2026-02-26 | $187.22M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $56.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $98.24M derived: sum of 2 quarters · filed 2026-02-26 | $154.62M derived: sum of 3 quarters · filed 2026-02-26 | $194.62M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $42.05M 10-Q · filed 2024-11-07 | $98.42M derived: sum of 2 quarters · filed 2024-11-07 | $138.43M 10-Q · filed 2024-11-07 | $194.21M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $56.38M 10-Q · filed 2024-08-08 | $96.38M 10-Q · filed 2024-08-08 | $152.16M derived: sum of 3 quarters · filed 2024-08-08 | $200.88M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $40.01M 10-Q · filed 2024-05-09 | $40.13M 10-Q · filed 2023-05-08 | $95.79M derived: sum of 2 quarters · filed 2024-05-09 | $144.50M derived: sum of 3 quarters · filed 2024-05-09 | $270.87M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $55.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $104.50M derived: sum of 2 quarters · filed 2024-03-14 | $230.86M derived: sum of 3 quarters · filed 2024-03-14 | $292.48M 10-K · filed 2024-03-14 | $292.60M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $48.71M 10-Q · filed 2023-11-08 | $48.96M 10-Q · filed 2022-11-03 | $175.08M derived: sum of 2 quarters · filed 2023-11-08 | $236.70M 10-Q · filed 2023-11-08 | $237.42M 10-Q · filed 2022-11-03 | $294.45M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $126.36M 10-Q · filed 2023-08-28 | $126.76M 10-Q · filed 2022-08-04 | $187.99M 10-Q · filed 2023-08-28 | $188.46M 10-Q · filed 2022-08-04 | $245.74M derived: sum of 3 quarters · filed 2023-08-28 | $294.50M derived: sum of 4 quarters · filed 2023-08-28 | ||
| 2022-03-31 | $61.70M 10-Q · filed 2023-05-08 | $119.38M derived: sum of 2 quarters · filed 2023-08-28 | $168.13M derived: sum of 3 quarters · filed 2023-08-28 | $221.04M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2021-12-31 | $57.68M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $106.43M derived: sum of 2 quarters · filed 2023-08-28 | $159.35M derived: sum of 3 quarters · filed 2023-08-28 | $211.65M 10-K/A · filed 2023-08-28 | $213.58M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $48.76M 10-Q · filed 2022-11-03 | $101.67M derived: sum of 2 quarters · filed 2022-11-03 | $153.97M 10-Q · filed 2022-11-03 | $210.01M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2021-06-30 | $52.91M 10-Q · filed 2022-08-04 | $105.22M 10-Q · filed 2022-08-04 | $161.25M derived: sum of 3 quarters · filed 2023-08-28 | $221.24M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2021-03-31 | $52.30M 10-Q · filed 2022-05-09 | $108.34M derived: sum of 2 quarters · filed 2023-08-28 | $168.33M derived: sum of 3 quarters · filed 2023-08-28 | $258.47M derived: sum of 4 quarters · filed 2023-08-28 | ||||
| 2020-12-31 | $56.04M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $116.02M derived: sum of 2 quarters · filed 2023-08-28 | $206.17M derived: sum of 3 quarters · filed 2023-08-28 | $294.64M 10-K/A · filed 2023-08-28 | $295.31M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $59.99M 10-Q · filed 2021-11-04 | $150.13M derived: sum of 2 quarters · filed 2021-11-04 | $238.61M 10-Q · filed 2021-11-04 | $308.16M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $90.14M 10-Q · filed 2021-08-05 | $178.62M 10-Q · filed 2021-08-05 | $248.18M derived: sum of 3 quarters · filed 2022-03-01 | $340.15M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $88.48M 10-Q · filed 2021-05-10 | $158.03M derived: sum of 2 quarters · filed 2022-03-01 | $250.01M derived: sum of 3 quarters · filed 2022-03-01 | $350.81M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $69.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $161.53M derived: sum of 2 quarters · filed 2022-03-01 | $262.33M derived: sum of 3 quarters · filed 2022-03-01 | $335.00M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $91.98M 10-Q · filed 2020-11-05 | $192.78M derived: sum of 2 quarters · filed 2020-11-05 | $265.45M 10-Q · filed 2020-11-05 | $325.30M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $100.80M 10-Q · filed 2020-08-10 | $173.47M 10-Q · filed 2020-08-10 | $233.32M derived: sum of 3 quarters · filed 2021-02-25 | $286.49M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $72.67M 10-Q · filed 2020-05-05 | $132.52M derived: sum of 2 quarters · filed 2021-02-25 | $185.69M derived: sum of 3 quarters · filed 2021-02-25 | $234.48M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $59.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $113.02M derived: sum of 2 quarters · filed 2021-02-25 | $161.81M derived: sum of 3 quarters · filed 2021-02-25 | $207.74M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $53.17M 10-Q · filed 2019-11-12 | $101.96M derived: sum of 2 quarters · filed 2019-11-12 | $147.89M 10-Q · filed 2019-11-12 | $238.45M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | $48.79M 10-Q · filed 2019-08-08 | $94.72M 10-Q · filed 2019-08-08 | $185.28M derived: sum of 3 quarters · filed 2020-03-12 | $226.56M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | $45.93M 10-Q · filed 2019-05-09 | $136.49M derived: sum of 2 quarters · filed 2020-03-12 | $177.77M derived: sum of 3 quarters · filed 2020-03-12 | $206.29M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | $90.56M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $131.84M derived: sum of 2 quarters · filed 2020-03-12 | $160.36M derived: sum of 3 quarters · filed 2020-03-12 | $181.23M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | $41.28M 10-Q · filed 2018-11-08 | $69.80M derived: sum of 2 quarters · filed 2018-11-08 | $90.67M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $28.52M 10-Q · filed 2018-08-08 | $49.38M 10-Q · filed 2018-08-08 | ||||||
| 2016-12-31 | $1.53M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |